menu search

OCUP / Ocuphire Pharma to Present at Wet AMD & DME Drug Development Summit in Boston, MA

Ocuphire Pharma to Present at Wet AMD & DME Drug Development Summit in Boston, MA
FARMINGTON HILLS, Mich., April 06, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced that Mina Sooch, MBA, Founder and CEO, will review the opportunity for APX3330, a Phase 2b oral small molecule inhibitor of novel target Ref-1 in diabetic eye disease at the Wet AMD & DME Drug Development Summit today, Wednesday, April 6 in Boston, MA. Ms. Sooch will also participate in a panel discussion titled, “The Race to Market Share: Is the answer ending the burden of monthly treatments?” Mitch Brigell, Ph.D., Head of Clinical Development and Strategy at Ocuphire, will moderate a panel discussion on “Future Therapies Targeting Novel Mechanisms Driving Wet AMD & DME” at the Summit. Read More
Posted: Apr 6 2022, 08:00
Author Name: GlobeNewsWire
Views: 102011

OCUP News  

Viatris and Ocuphire Pharma get FDA green light for eye treatment

By Market Watch
September 27, 2023

Viatris and Ocuphire Pharma get FDA green light for eye treatment

Viatris Inc. VTRS, and Ocuphire Pharma Inc. OCUP, +3.08% said Wednesday that the U.S. Food and Drug Administration has approved Ryzumvi to treat the s more_horizontal

Ocuphire Pharma Plunges Following CEO Termination, New Appointment: The Bull, Bear Case - Ocuphire Pharma (NASDAQ:OCUP)

By Benzinga
April 21, 2023

Ocuphire Pharma Plunges Following CEO Termination, New Appointment: The Bull, Bear Case - Ocuphire Pharma (NASDAQ:OCUP)

Ocuphire Pharma Inc OCUP was plunging over 22% at one point on Friday after the company announced it appointed Rick Rodgers to the role of interim CE more_horizontal

Wall Street Analysts Believe Ocuphire Pharma, Inc. (OCUP) Could Rally 257.14%: Here's is How to Trade

By Zacks Investment Research
April 21, 2023

Wall Street Analysts Believe Ocuphire Pharma, Inc. (OCUP) Could Rally 257.14%: Here's is How to Trade

The consensus price target hints at a 257.1% upside potential for Ocuphire Pharma, Inc. (OCUP). While empirical research shows that this sought-after more_horizontal

Ocuphire Pharma, Inc. (OCUP) Is a Great Choice for 'Trend' Investors, Here's Why

By Zacks Investment Research
April 21, 2023

Ocuphire Pharma, Inc. (OCUP) Is a Great Choice for 'Trend' Investors, Here's Why

Ocuphire Pharma, Inc. (OCUP) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit fro more_horizontal

Does Ocuphire Pharma, Inc. (OCUP) Have the Potential to Rally 323.89% as Wall Street Analysts Expect?

By Zacks Investment Research
April 5, 2023

Does Ocuphire Pharma, Inc. (OCUP) Have the Potential to Rally 323.89% as Wall Street Analysts Expect?

The mean of analysts' price targets for Ocuphire Pharma, Inc. (OCUP) points to a 323.9% upside in the stock. While this highly sought-after metric has more_horizontal

Here's Why Momentum in Ocuphire Pharma, Inc. (OCUP) Should Keep going

By Zacks Investment Research
April 5, 2023

Here's Why Momentum in Ocuphire Pharma, Inc. (OCUP) Should Keep going

Ocuphire Pharma, Inc. (OCUP) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound more_horizontal

Why Is Ocuphire Pharma (OCUP) Stock Down 20% Today?

By InvestorPlace
January 26, 2023

Why Is Ocuphire Pharma (OCUP) Stock Down 20% Today?

Ocuphire Pharma (NASDAQ: OCUP ) stock is falling on Thursday after the company posted results from a Phase 2 clinical trial. The clinical trial evalua more_horizontal

Ocuphire Pharma to Present at Wet AMD & DME Drug Development Summit in Boston, MA

By GlobeNewsWire
April 6, 2022

Ocuphire Pharma to Present at Wet AMD & DME Drug Development Summit in Boston, MA

FARMINGTON HILLS, Mich., April 06, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical compan more_horizontal


Search within

Pages Search Results: